Legislator Jurisprudence & Législation
DE FR IT EN
Analyser dans Legislator
3 B 40/17, 3 B 40/17 (3 C 20/18) ECLI:DE:BVerwG:2018:181218B3B40.17.0 Généré par l'IA

Compatibility of statutory pharmaceutical price binding with prohibition of nationality discrimination under Article 3(1) of the Basic Law

Numéro de cause 3 B 40/17, 3 B 40/17 (3 C 20/18)
Autorité / Tribunal
Juridiction Allemagne (DE)
Date de la décision
Issue du litige Admis (Allowed)
Ouvrir la source officielle Version Markdown lisible par machine (.md)

Synthèse Legislator

Généré par l'IA

The Federal Administrative Court (BVerwG) granted the plaintiff's complaint, allowing the appeal on the ground that the case possesses fundamental significance, and set a provisional amount in dispute for the revision proceedings. The dispute concerns the validity of the statutory price binding for pharmaceuticals applicable to domestic pharmacies, specifically challenging whether this regulation violates the prohibition of discrimination against German nationals in the cross-border provision of healthcare services, as established by the European Court of Justice. The decisive legal question involves the compatibility of the domestic price binding mechanism under § 78 Abs. 1 and 2 of the German Medicines Act (AMG) and § 3 of the Pharmaceuticals Pricing Regulation (AMPreisV) with Article 12(1) of the EU Charter of Fundamental Rights and Article 3(1) of the German Basic Law, following the CJEU's judgment in the Deutsche Parkinson Vereinigung case.

Regeste Legislator

Généré par l'IA

§ 132 Abs. 2 Nr. 1 VwGO, Art. 3 Abs. 1 GG, § 63 Abs. 1 Satz 1 GKG, § 47 Abs. 1, § 52 Abs. 2 und § 63 Abs. 1 Satz 1 GKG; Compatibility of statutory pharmaceutical price binding with prohibition of nationality discrimination under Article 3(1) of the Basic Law: The dispute concerns the validity of the statutory price binding for pharmaceuticals applicable to domestic pharmacies, specifically challenging whether this regulation violates the prohibition of discrimination against German nationals in the cross-border provision of healthcare services, as established by the European Court of Justice. The decisive legal question involves the compatibility of the domestic price binding mechanism under § 78 Abs. 1 and 2 of the German Medicines Act (AMG) and § 3 of the Pharmaceuticals Pricing Regulation (AMPreisV) with Article 12(1) of the EU Charter of Fundamental Rights and Article 3(1) of the German Basic Law, following the CJEU's judgment in the Deutsche Parkinson Vereinigung case.

Mots-clés

Généré par l'IA
interdiction de discrimination prétention légale droits fondamentaux nationalité montant de base prestation de services

Dispositions légales citées

Généré par l'IA
§ 132 Abs. 2 Nr. 1 VwGO
The legal basis for granting the complaint and allowing the appeal due to the fundamental significance of the case.
Art. 3 Abs. 1 GG
1, Art. 3 Abs. 1 GG unvereinbar ist.
§ 63 Abs. 1 Satz 1 GKG
2 und § 63 Abs. 1 Satz 1 GKG.
§ 47 Abs. 1, § 52 Abs. 2 und § 63 Abs. 1 Satz 1 GKG
The procedural rules applied to determine the provisional amount in dispute for the revision proceedings.
Généré par l'IA
3 B 41/17, 3 B 41/17 (3 C 21/18)
Statutory pharmacy price binding's compatibility with equal treatment under Art. 3, 12 GG following ECJ ruling on national discrimination
I ZR 74/24
Incompatibility of domestic drug price-binding extended to foreign mail-order pharmacies with EU freedom of goods movement
I ZR 72/08
Extraterritorial application of German pharmaceutical price binding to cross-border mail-order drug sales
3 C 21/18
Validity of domestic pharmaceutical price binding despite EU-wide exemption for foreign mail-order pharmacies
2 BvR 787/16
Extension of German pharmaceutical price binding to foreign online pharmacies: conflict with EU free movement and national constitutional rights

Questions juridiques clés extraites par Legislator

Généré par l'IA
§ 132 Abs. 2 Nr. 1 VwGO

The legal basis for granting the complaint and allowing the appeal due to the fundamental significance of the case.

§ 47 Abs. 1, § 52 Abs. 2 und § 63 Abs. 1 Satz 1 GKG

The procedural rules applied to determine the provisional amount in dispute for the revision proceedings.

Vous souhaitez savoir comment cet arrêt s'applique à votre dossier ?

Analysez cette décision avec la législation fédérale, le droit cantonal, la doctrine et la jurisprudence subséquente dans Legislator AI.

Ouvrir dans Legislator →

Texte complet

Revisionszulassung; Inländerdiskriminierung; zur Preisbindung von Arzneimitteln für inländische Apotheken

[GRUENDE]

Die Beschwerde der Klägerin hat Erfolg. Der Rechtssache kommt die geltend gemachte grundsätzliche Bedeutung (§ 132 Abs. 2 Nr. 1 VwGO) zu. Das Revisionsverfahren wird dem Bundesverwaltungsgericht voraussichtlich Gelegenheit zur Klärung der Frage geben, ob die für inländische Apotheken geltende Preisbindung für Arzneimittel (§ 78 Abs. 1 und 2 AMG, § 3 AMPreisV) in Folge des Urteils des Gerichtshofs der Europäischen Union vom 19. Oktober 2016 - C-148/15 [ECLI:EU:C:2016:776], Deutsche Parkinson Vereinigung - (NVwZ 2016, 1793) wegen "Inländerdiskriminierung" mit Art. 12 Abs. 1, Art. 3 Abs. 1 GG unvereinbar ist.

Die vorläufige Streitwertfestsetzung für das Revisionsverfahren beruht auf § 47 Abs. 1, § 52 Abs. 2 und § 63 Abs. 1 Satz 1 GKG.